LesiaKDropulicMD

Infectious Disease • Bethesda, MD

Transplant/Immunocompromised States

Staff Clinician: The National Institutes of Health, NIAID, Laboratory of Infectious Diseases

Join to view full profile

Dr. Dropulic is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dropulic's full profile

Already have an account?

Office
10 Center Dr
BG 10, Rm. 6D44D
Bethesda, MD 20892
Phone+1 301-496-7675

Education & Training

Johns Hopkins UniversityFellowship, Infectious Disease, 1992 - 1997
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1989 - 1992
Wayne State University School of MedicineClass of 1989

Certifications & Licensure

MD State Medical License 1992 - 2026

Clinical Trials

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise Start of enrollment: 2009 Oct 01
Recruiting
Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection Start of enrollment: 2013 Sep 26
Completed
Phase 1
Challenge Infection of Healthy Adult Volunteers With RSV A2 Start of enrollment: 2018 Feb 20
Completed
Phase 1

Publications & Presentations

PubMed

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.
Joseph P Casazza, Amelia R Hofstetter, Pamela J M Costner, LaSonji A Holman, Cynthia S Hendel
NPJ Vaccines. 2024-09-17
5 citations
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.
Kirsten E Lyke, Andrea A Berry, Kaitlin Mason, Azza H Idris, Mark O'Callahan
The Lancet. Infectious Diseases. 2023-05-01
30 citations
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.
Alicia T Widge, Amelia R Hofstetter, Katherine V Houser, Seemal F Awan, Grace L Chen
Science Translational Medicine. 2023-04-19

Other Languages

Ukrainian